Clinical trial
Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
NCT00006630 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00006630 |
|---|---|
| Title | Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection |
| Official title | Open-Label, Multi-Site Study for the Administration of Vaccinia Immune Globulin (Human) To Subjects Who Experience Complications From Vaccinia Virus Vaccinations or To Unprotected Individuals Accidentally Exposed To Vaccinia Virus or Related Orthopox Viruses [During HIV Vaccine Research] |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy, Communicable Diseases |
| Intervention type | Drug |
| Interventions | Vaccinia Immune Globulin (Human) |
| Enrollment | 0 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: